Xvivo Perfusion AB (publ)

OM:XVIVO Stock Report

Market Cap: SEK 8.6b

Xvivo Perfusion Valuation

Is XVIVO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of XVIVO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: XVIVO (SEK273) is trading below our estimate of future cash flow value (SEK343.5)

Significantly Below Future Cash Flow Value: XVIVO is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XVIVO?

Key metric: As XVIVO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for XVIVO. This is calculated by dividing XVIVO's market cap by their current earnings.
What is XVIVO's PE Ratio?
PE Ratio116.4x
EarningsSEK 73.86m
Market CapSEK 8.60b

Price to Earnings Ratio vs Peers

How does XVIVO's PE Ratio compare to its peers?

The above table shows the PE ratio for XVIVO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27x
VIMIAN Vimian Group
39.6x26.22%SEK 15.9b
ARJO B Arjo
18.9x21.32%SEK 6.6b
RAY B RaySearch Laboratories
33.7x22.56%SEK 7.5b
AMBEA Ambea
15.7x11.94%SEK 11.2b
XVIVO Xvivo Perfusion
116.4x50.59%SEK 8.6b

Price-To-Earnings vs Peers: XVIVO is expensive based on its Price-To-Earnings Ratio (116.4x) compared to the peer average (27x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does XVIVO's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
XVIVO 116.4xIndustry Avg. 24.8xNo. of Companies12PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: XVIVO is expensive based on its Price-To-Earnings Ratio (116.4x) compared to the European Medical Equipment industry average (24.6x).

Price to Earnings Ratio vs Fair Ratio

What is XVIVO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XVIVO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio116.4x
Fair PE Ratio62.5x

Price-To-Earnings vs Fair Ratio: XVIVO is expensive based on its Price-To-Earnings Ratio (116.4x) compared to the estimated Fair Price-To-Earnings Ratio (62.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XVIVO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 273.00
SEK 350.00
+28.21%
6.45%SEK 385.00SEK 320.00n/a5
Jun ’27SEK 267.80
SEK 350.00
+30.69%
6.45%SEK 385.00SEK 320.00n/a5
May ’27SEK 274.40
SEK 337.00
+22.81%
8.37%SEK 385.00SEK 300.00n/a5
Apr ’27SEK 245.80
SEK 302.00
+22.86%
15.27%SEK 385.00SEK 245.00n/a5
Mar ’27SEK 187.50
SEK 301.00
+60.53%
15.49%SEK 385.00SEK 245.00n/a5
Feb ’27SEK 225.20
SEK 333.60
+48.13%
15.79%SEK 408.00SEK 275.00n/a5
Jan ’27SEK 186.60
SEK 319.60
+71.28%
21.22%SEK 408.00SEK 225.00n/a5
Dec ’26SEK 178.10
SEK 319.60
+79.45%
21.22%SEK 408.00SEK 225.00n/a5
Nov ’26SEK 189.50
SEK 319.60
+68.65%
21.22%SEK 408.00SEK 225.00n/a5
Oct ’26SEK 169.60
SEK 331.60
+95.52%
23.68%SEK 425.00SEK 215.00n/a5
Sep ’26SEK 177.00
SEK 345.60
+95.25%
21.47%SEK 425.00SEK 215.00n/a5
Aug ’26SEK 197.40
SEK 346.00
+75.28%
21.54%SEK 425.00SEK 215.00n/a5
Jul ’26SEK 287.20
SEK 446.00
+55.29%
15.13%SEK 520.00SEK 320.00n/a6
Jun ’26SEK 306.40
SEK 448.50
+46.38%
14.02%SEK 520.00SEK 335.00SEK 267.806
May ’26SEK 319.20
SEK 448.50
+40.51%
14.02%SEK 520.00SEK 335.00SEK 274.406
Apr ’26SEK 291.50
SEK 476.17
+63.35%
17.05%SEK 567.00SEK 325.00SEK 245.806
Mar ’26SEK 444.00
SEK 518.67
+16.82%
8.84%SEK 567.00SEK 460.00SEK 187.506
Feb ’26SEK 466.00
SEK 522.00
+12.02%
8.06%SEK 567.00SEK 480.00SEK 225.206
Jan ’26SEK 489.00
SEK 538.17
+10.05%
7.79%SEK 584.00SEK 480.00SEK 186.606
Dec ’25SEK 480.00
SEK 538.17
+12.12%
7.79%SEK 584.00SEK 480.00SEK 178.106
Nov ’25SEK 448.00
SEK 545.67
+21.80%
6.26%SEK 584.00SEK 480.00SEK 189.506
Oct ’25SEK 503.00
SEK 549.00
+9.15%
6.57%SEK 584.00SEK 480.00SEK 169.606
Sep ’25SEK 533.00
SEK 549.00
+3.00%
6.57%SEK 584.00SEK 480.00SEK 177.006
Aug ’25SEK 506.00
SEK 549.00
+8.50%
6.57%SEK 584.00SEK 480.00SEK 197.406
Jul ’25SEK 418.00
SEK 440.00
+5.26%
13.89%SEK 520.00SEK 340.00SEK 287.206
Jun ’25SEK 440.00
SEK 408.00
-7.27%
12.02%SEK 468.00SEK 340.00SEK 306.406
SEK 350
Fair Value
22.0% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 21:52
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Simon LarssonDanske Bank
Jonatan AnderssonDNB Carnegie